Self-screen B.V. news

This year ECCMID 2021 conference is still fully virtual, nevertheless the data presented are real! Self-screen is proud to announce that the QIAGEN NeuMoDx HPV Test Strip Assay fulfills the International Guidelines for HPV Testing, the so-called Meijer criteria. The data are presented during the QIAGEN symposium on July 12th by dr. Anja Šterbenc MD, PhD from Prof. dr. Mario Poljak’s lab (Institute of Microbiology and Immunology Faculty of Medicine, University of Ljubljana, Sloven

Self-screen is proud to announce the appointment of Michelle Meijer, PhD, as the companies Chief Commercial Officer. Michelle brings over 25 years of business experience in the life sciences and molecular diagnostics field, of which more than 15 years in the field of cervical cancer prevention and HPV diagnostics in particular. She held several senior business development and management roles at Roche Diagnostics and QIAGEN, around the years that The Netherlands was preparing for primary HPV

Self-screen’s Chief Scientific Officer dr. Bart Hesselink talks about the clinical validation of QIAGEN’s next generation HPV screening assay on the NeuMoDxTM Molecular Systems. The NeuMoDxTM 288 and NeuMoDxTM96 Molecular Systems are fully automated continuous random-access analyzers that perform adequately in standardized, high volume cervical cancer HPV screening laboratories. The HPV Test Strip is fully compliant with

British Journal of Cancer; https://doi.org/10.1038/s41416-021-01614-4

Primary HPV screening has doubled the number of colposcopy referrals because of direct referral of HPV-positive women with ASC-US/ LSIL cytology.

This study evaluated the CIN3+ risks and colposcopy referrals by

• QIAsure Methylation Test analysis
• HPV16/18 genotyping
• HPV16/18/31/33/45 genotyping
<